Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas - Contacts and Locations

Home

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

This study has been completed.

Study NCT00035022. Last updated on January 12, 2006. Information provided by BioCryst Pharmaceuticals

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035022

Locations

Sponsors and Collaborators

BioCryst Pharmaceuticals

Investigators


Principal Investigator:	Deborah A. Thomas, M.D.	M.D. Anderson Cancer Center